The success of CDK4/6 inhibitors such as abemaciclib (MONARCH studies), ribociclib (MONALEESA studies), as well as palbociclib (PALOMA studies), in combination with endocrine therapy, has been demonstrated in a number of trials in ER‐positive BC.111, 112, 113, 114, 115, 116. The gene discussed is CDK4; the disease is breast cancer.